Determination of the activity of standard anti-tuberculosis drugs against intramacrophage Mycobacterium tuberculosis, in vitro: MGIT 960 as a viable alternative for BACTEC 460

Jhamb, Sarbjit Singh; Goyal, Amit K.; Singh, Prati Pal

doi:10.1016/j.bjid.2013.12.004

Cited by 10 publications

(8 citation statements)

References 17 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparing to the MTB susceptibility to INH, BCG Connaught seemed to be quite similar to MTB and M. bovis, while BCG Pasteur was less susceptible. The previously published results showed that INH was highly effective against intracellular MTB as it inhibited more than 99% at 0.20 µg/ml after 7 days' treatment (Wright et al, 1996 andJhamb et al, 2014). In addition, INH obtainable serum level in human (4 µg/ml) caused 97.6% & 99.2% inhibition of MTB and M. bovis inside J774 cells after 5 days' treatment, respectively (Rastogi et al, 1987) or 99.65% after 7 days (Rastogi et al, 1996).…”

Section: Discussionmentioning

confidence: 85%

“…The bacterial pellet was re-suspended in DMEM supplemented with 10 % FBS. (Rastogi and Blom-Potar, 1990;Talaue et al, 2006;Andreu et al, 2012 andJhamb et al, 2014): J774A.1 cells were seeded at a concentration of 1×10 4 cells/ well in 96-well tissue culture white plates with clear bottoms(Corning®) 24 hours prior to infection (until the cells became spindle). After washing, the cells were infected with 100 µl of prepared BCG suspension (multiplicity of infection, MOI, 1-10: 1).…”

Section: Mts Cell Proliferation Assay or Cytotoxicitymentioning

confidence: 99%

See 1 more Smart Citation

Screening the activity of anti-tuberculosis drugs against M. bovis BCG Connaught and M. bovis BCG Pasteur growing in J774A.1 cell line macrophages

Tawab

Nasr

Sriranganathan

et al. 2016

Benha Veterinary Medical Journal

View full text Add to dashboard Cite

Mycobacterium bovis BCG is attenuated strain derived from M. bovis. It has been known to prevent childhood pulmonary and meningeal tuberculosis and to treat superficial bladder cancer as immunotherapy. Administration of BCG has been restricted to immune-deficient individuals since 2007 because of its combined complications. Which treated with antituberculosis drugs based on assumption is fully responsive to these drugs. BCG Connaught showed more susceptibility to the activity of isoniazid, ethambutol, kanamycin, ofloxacin, streptomycin, amikacin and capreomycin than BCG Pasteur growing in J774A.1 cells. While the activity of rifampicin and levofloxacin was the same between the two tested strains. The spectrum of intracellular drug action can be ordered based on a decreasing order of inhibitory activity, as following rifampin > isoniazid > ethambutol > streptomycin > kanamycin> amikacin> ofloxacin> capreomycin> levofloxacin against BCG Connaught. While rifampin > isoniazid > ethambutol > kanamycin = streptomycin > ofloxacin> amikacin> levofloxacin> capreomycin for BCG Pasteur. There is a very limited publications describe the activity of antituberculosis drugs against intracellular growing BCG strains.

show abstract

Section: Discussionmentioning

confidence: 85%

Section: Mts Cell Proliferation Assay or Cytotoxicitymentioning

confidence: 99%

Screening the activity of anti-tuberculosis drugs against M. bovis BCG Connaught and M. bovis BCG Pasteur growing in J774A.1 cell line macrophages

Tawab

Nasr

Sriranganathan

et al. 2016

Benha Veterinary Medical Journal

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

“…The antimycobacterial activity of NSC757963 was tested against the standard reference strain of Mycobacterium tuberculosis H37Rv that is commonly used in evaluating the antimycobacterial activity of drugs [ 36 , 37 ]. We used the BACTEC MGIT 960 SIRE system to determine the values of MIC, as this method proved to be highly stable, reproducible and accurate compared to other commonly used methods [ 36 , 37 ]. Susceptibility of the H37Rv strain to control drugs displayed in Table 5 showed that the experimental procedures are held correctly and that the sensitivity of the tested strain is suitable for the antimycobacterial activity evaluation of our compound (Streptomycin, Isoniazid, Rifampin, and Ethambutol with MIC values 0.1 μg/mL~ 5 μg/mL).…”

Section: Resultsmentioning

confidence: 99%

Novel Anthra[1,2-c][1,2,5]Thiadiazole-6,11-Diones as Promising Anticancer Lead Compounds: Biological Evaluation, Characterization & Molecular Targets Determination

et al. 2016

View full text Add to dashboard Cite

The novel compounds NSC745885 and NSC757963 developed at our laboratory were tested against a panel of 60 cancer cell lines at the National Cancer Institute, USA, and a panel of 39 cancer cell lines at the Japanese Foundation of Cancer Research. Both compounds demonstrated selective unique multi-log differential patterns of activity, with GI50 values in the sub-micro molar range against cancer cells rather than normal cardiac cells. NSC757963 showed high selectivity towards the leukemia subpanel. Activities of both compounds strongly correlated to expression of NFKB1 and CSNK2B genes, implying that they may inhibit the NF-κB pathway. Immunocytochemical microscopy of OVCAR-3 cells showed clear cytosolic accumulation of the NF-κB p65 subunit following treatment. Western blotting showed dose dependent inhibition of the nuclear expression of the NF-κB p65 subunit with subsequent accumulation in the cytosol following treatment. Docking experiments showed binding of both compounds to the NF-κB activator IKKβ subunit preventing its translocation to the nucleus. Collectively, these results confirm the ability of our compounds to inhibit the constitutively active NF-κB pathway of OVCAR-3 cells. Furthermore, COMPARE analysis indicated that the activity of NSC757963 is similar to the antituberculosis agent rifamycin SV, this was confirmed by testing the antimycobacterial activity of NSC757963 against Mycobacterium tuberculosis, results revealed potent activity suitable for use in clinical practice. Molecular properties and Lipinski’s parameters predicted acceptable bioavailability properties with no indication of mutagenicity, tumorigenicity, irritability and reproductive effects. Oral absorption experiments using the human Caco-2 model showed high intestinal absorption of NSC745885 by passive transport mechanism with no intestinal efflux or active transport mechanisms. The unique molecular characterization as well as the illustrated anticancer spectra of activity and bioavailability properties warrant further development of our compounds and present a foundation brick in the pre-clinical investigations to implement such compounds in clinical practice.

show abstract

“…The standard anti‐TB drugs isoniazid, rifampicin, ethambutol, and streptomycin have the ability to inhibit the laboratory strain of M tuberculosis (H37Rv) at concentrations of 0.025, 0.4, 0.5, and 1 μg/mL, respectively . These drugs also inhibit intracellular M tuberculosis H37Rv (that is, residing within macrophages) at concentrations of 0.2, 0.8, 8.0, and 5 μg/mL, respectively . The peptides HNP‐1, NP‐1, nisin A, E50‐52, rufomycin, ecumicin lassomycin, teixobactin, trichoderin A, trichoderin B, and BB‐3497 have been identified as potential anti‐TB drugs as they have similar MICs against laboratory strains.…”

Section: Discussionmentioning

confidence: 99%

A review on anti‐tuberculosis peptides: Impact of peptide structure on anti‐tuberculosis activity

Yathursan

Wiles

Read

et al. 2019

Journal of Peptide Science

View full text Add to dashboard Cite

Antibiotic resistance is a major public health problem globally. Particularly concerning amongst drug‐resistant human pathogens is Mycobacterium tuberculosis that causes the deadly infectious tuberculosis (TB) disease. Significant issues associated with current treatment options for drug‐resistant TB and the high rate of mortality from the disease makes the development of novel treatment options against this pathogen an urgent need. Antimicrobial peptides are part of innate immunity in all forms of life and could provide a potential solution against drug‐resistant TB. This review is a critical analysis of antimicrobial peptides that are reported to be active against the M tuberculosis complex exclusively. However, activity on non‐TB strains such as Mycobacterium avium and Mycobacterium intracellulare, whenever available, have been included at appropriate sections for these anti‐TB peptides. Natural and synthetic antimicrobial peptides of diverse sequences, along with their chemical structures, are presented, discussed, and correlated to their observed antimycobacterial activities. Critical analyses of the structure allied to the anti‐mycobacterial activity have allowed us to draw important conclusions and ideas for research and development on these promising molecules to realise their full potential. Even though the review is focussed on peptides, we have briefly summarised the structures and potency of the various small molecule drugs that are available and under development, for TB treatment.

show abstract

Determination of the activity of standard anti-tuberculosis drugs against intramacrophage Mycobacterium tuberculosis, in vitro: MGIT 960 as a viable alternative for BACTEC 460

Cited by 10 publications

References 17 publications

Screening the activity of anti-tuberculosis drugs against M. bovis BCG Connaught and M. bovis BCG Pasteur growing in J774A.1 cell line macrophages

Screening the activity of anti-tuberculosis drugs against M. bovis BCG Connaught and M. bovis BCG Pasteur growing in J774A.1 cell line macrophages

Novel Anthra[1,2-c][1,2,5]Thiadiazole-6,11-Diones as Promising Anticancer Lead Compounds: Biological Evaluation, Characterization & Molecular Targets Determination

A review on anti‐tuberculosis peptides: Impact of peptide structure on anti‐tuberculosis activity

Contact Info

Product

Resources

About